Skip to content

Serum Concentrations of Pregnancy-associated Proteins for Assessment of Gestational Age Before Abortion

Serum Concentrations of Pregnancy-associated Proteins for Assessment of Gestational Age Before Abortion

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04232189
Enrollment
275
Registered
2020-01-18
Start date
2019-11-12
Completion date
2020-04-14
Last updated
2021-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy

Keywords

placental protein, gestational age, abortion

Brief summary

This will be a case-series multicenter study enrolling 800 pregnant people. Serum will be collected from people seeking abortion and assayed at a qualified laboratory.

Detailed description

Knowledge of gestational age (GA) is essential for guiding abortion care. In 2016, Gynuity Health Projects (GHP) launched a portfolio of research that aims to explore the possibility of developing a blood or urine test for this purpose.The goal of the present study is to validate initial study findings (protocol 8000) in a larger population of people seeking abortion. Staff will obtain a serum specimen from each participant before any cervical manipulation is performed and before any abortifacient drug is administered. The site will send the specimens to a central facility for storage until assay. Serum assays for PAPP-A and possibly other proteins will be performed at a selected laboratory by qualified experts.

Interventions

OTHERno intervention

no intervention, just specimen collection

Sponsors

Family Planning Associates Medical Group, LTD
CollaboratorOTHER
Planned Parenthood of Greater New York
CollaboratorOTHER
Presidential Women's Center
CollaboratorUNKNOWN
Gynuity Health Projects
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
FEMALE

Inclusion criteria

* Pregnant and seeking medical or surgical abortion * Has had or will have an ultrasound on the day of study enrollment or earlier during the current pregnancy * Able to provide blood and urine specimens before any trans-cervical procedure or mifepristone ingestion * Not previously enrolled in this study

Exclusion criteria

* Does not meet Inclusion Criteria

Design outcomes

Primary

MeasureTime frameDescription
Negative Predictive Value 70 days1 dayNegative Predictive Value of Prespecified Protein Concentration in Serum for Predicting a GA of ≤70 days is \>95%
Negative Predictive Value 105 days1 dayNegative Predictive Value of Prespecified Protein Concentration in Serum for Predicting a GA of ≤105 days is \>95%

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026